

04/27/2009

U.S. Application No. 10/806,793
Attorney Docket No. 19313-001 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Johansen <i>et al.</i>	Confirmation No.:	2372
SERIAL NUMBER:	10/806,793	EXAMINER :	Chang Yu Wang
FILING DATE:	March 22, 2004	ART UNIT :	1649
FOR:	NOVEL NEUROTROPHIC FACTORS		

*Mail Stop AF*Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450DECLARATION UNDER 37 C.F.R. §1.132

I, Teit Johansen, hereby declare and state as follows:

1. I am a named inventor in the above-identified patent application. I am the President and CEO of the assignee of this application, NsGene, a Danish biotechnology company. I have been working in the field of molecular biology since 1984. I hold a PhD in Molecular Biology from the University of Copenhagen. Between 1986 and 1991 I conducted research in molecular biology at the Danish University Hospital, Rigshospitalet. From 1991 through 1994 I worked at Johns Hopkins University in Baltimore, Maryland (in various positions up to Assistant Professor) in the field on molecular biology. From 1994 through 1999 I worked at Neurosearch A/S, in Copenhagen, Denmark, to establish the molecular biology capability of that company. In 1999, I founded NsGene.
2. I am an inventor of the present invention and am familiar with the contents of this application. I have reviewed the Office Action of December 9, 2008 relating to this application and the references cited therein.
4. I understand that the Examiner has maintained an obviousness rejection over the teachings of Yan (U.S. Patent No. 5,641,749) and Milbrandt (U.S. Patent No. 6,284,540). Yan is cited by the Examiner for its teaching that injury of retinal ganglion cells may be treated by administering glial cell line-derived neurotrophic factor (GDNF). Milbrandt is cited by the